Fuse Diagnostics has successfully secured £1.6 million in seed funding from a group of angel investors and Innovate UK. This capital injection will support the development of a new range of diagnostic testing products that provide laboratory-standard performance in rapid, low-cost formats. The products aim to serve sectors such as industrial, food, and water testing, as well as clinical diagnostics and veterinary applications. Fuse Diagnostics, led by CEO Dr. Harry Lamble, is focusing on two primary product lines: Flip for basic industrial and bioprocessing tests and Apex for advanced diagnostics. The company is an initiative by the founders of Sense Biodetection, who previously created the world’s first rapid instrument-free molecular diagnostic test (Veros COVID-19). The funding will enable Fuse to further innovate in the field of pathogen testing, addressing critical needs for fast and reliable diagnostics.
Medical Technology (MedTech), Industrial Biotechnology, Veterinary Technology,United Kingdom